Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Scott Linacre

Physician Assistant, Surgical Lawrenceville, GA Physician Assistant

NPI 1295974566 CMS profile 10758501

631 Professional Dr, Suite 360, Lawrenceville, GA 30046

Open in the dashboard

General payments

$18,766

428 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Linacre of Lawrenceville, GA is reported in the CMS Open Payments database as having received $18,766 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,310 76
2024 General $5,559 85
2023 General $1,534 89
2022 General $2,482 94
2021 General $1,882 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Linacre
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Scott Linacre were reported at $7,310. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Scott Linacre Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,882 $111 $36–$285 $132
2022 $2,482 $126 $44–$350 $149
2023 $1,534 $137 $47–$355 $160
2024 $5,559 $146 $49–$384 $164
2025 $7,310 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $7,277 110 payments
  2. Curonix LLC $4,696 25 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,510 218 payments
  4. Nalu Medical, Inc. $844 4 payments
  5. Foundation Fusion Solutions, LLC $704 8 payments
  6. Vertos Medical, Inc. $606 5 payments
  7. Boston Scientific Corporation $509 11 payments
  8. Spinal Simplicity, LLC $425 4 payments
  9. Stryker Corporation $289 2 payments
  10. Collegium Pharmaceutical, Inc. $158 9 payments
  11. Other $748 32 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,550 409 payments
  2. Travel and Lodging $2,741 13 payments
  3. Consulting Fee $2,430 5 payments
  4. Education $45 1 payment
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $5,858 97 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $4,696 25 payments
  3. RELISTOR Gastroenterology $2,201 212 payments
  4. SYNCHROMEDII $1,119 11 payments
  5. Nalu Neurostimulation System $844 4 payments
  6. mild Device Kit $606 5 payments
  7. Superion $444 10 payments
  8. HA MINUTEMAN G3-R $425 4 payments
  9. RELISTOR Gastroenterology $315 7 payments
  10. VECTRIS $162 1 payment
  11. Other $2,080 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

2,149

Median for Physician Assistant: 241

Drug cost

$255,106

Median for Physician Assistant: $4,110

Branded share of claims

7.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Relistor Methylnaltrexone Bromide Brand 72 $192,625
Movantik Naloxegol Oxalate Brand 42 $20,060
Ztlido Lidocaine Brand 35 $12,901
Lidocaine Generic 62 $7,133
Gabapentin Generic 572 $6,565
Naloxone Hcl Generic 42 $2,713
Diclofenac Sodium Generic 155 $2,670
Tizanidine Hcl Generic 304 $2,545
Cyclobenzaprine Hcl Generic 250 $1,822
Celecoxib Generic 67 $1,719

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $138
$138 72 —
Xeomin
  • Merz Pharmaceuticals, LLC $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record